A5005311716- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Pediatric Hepatobiliary Diseases and Treatments
- Genetic factors in colorectal cancer
- Gastric Cancer Management and Outcomes
- Cancer-related molecular mechanisms research
- Esophageal Cancer Research and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- COVID-19 and healthcare impacts
- Hepatocellular Carcinoma Treatment and Prognosis
- MicroRNA in disease regulation
- Economic and Financial Impacts of Cancer
- RNA modifications and cancer
- Cancer Treatment and Pharmacology
- Liver Diseases and Immunity
- Cancer Diagnosis and Treatment
- Ferroptosis and cancer prognosis
- Lung Cancer Research Studies
- COVID-19 Clinical Research Studies
- Colorectal and Anal Carcinomas
- Neuroendocrine Tumor Research Advances
- Pancreatitis Pathology and Treatment
Memorial Sloan Kettering Cancer Center
2022-2025
Mater Misericordiae University Hospital
2021-2025
Cornell University
2022
Beaumont Hospital
2020-2021
University Hospital Galway
2013-2020
St. James's Hospital
2017
Johns Hopkins Hospital
2015
Background Gut microbiota composition can influence cancer immunotherapy response. Recent evidence suggests Helicobacter pylori infection may reduce immune checkpoint inhibitor (ICI) efficacy in lung and melanoma, but thorough characterization of this association patients with gastric is lacking. We aimed to determine the impact H. on survival population. Methods This single-center, retrospective study included all ICI-treated individuals metastatic documented status at Memorial Sloan...
626 Background: Although 40% of patients (pts) with advanced biliary tract cancer (BTC) harbor actionable alterations amenable to targeted therapy (TT), tumor genotyping can be challenging due limited tissue and other factors. Next generation sequencing (NGS) cell free DNA (cfDNA) may aid in prognostication, identification TT opportunities, characterization acquired resistance mechanisms TT. Methods: cfDNA was collected prospectively pts BTC treated at MSK from 2016-2023. Samples were...
555 Background: BTCs are genomically diverse. TT have established antitumor activity in a subset of pts that harbour actionable alterations; however, most patients (pts) do not respond to or experience acquired resistance on TT. We sought explore genomic mechanisms response across the spectrum BTCs. Methods: leveraged prospectively maintained cohort with histologically confirmed BTC who underwent molecular profiling using an FDA authorized, targeted, NGS assay. Additional clinicopathologic...
Subgroup analyses of randomized trials suggest the superiority immune checkpoint inhibitor-based therapy over chemotherapy in patients with mismatch-repair deficient (dMMR) and/or microsatellite instability-high (MSI-high) advanced gastric or gastroesophageal junction adenocarcinoma. However, these subgroups are small and studies examining prognostic features within dMMR/MSI-high lacking.We conducted an international cohort study at tertiary cancer centers collected baseline...
Mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) is the most common alteration in pancreatic ductal adenocarcinoma, and KRAS glycine to cystine substitution at codon 12 (G12C) mutations (KRAS G12Cmut) are observed 1%-2%. Several inhibitors of G12C have recently demonstrated promise solid tumors, including cancer. Little known regarding clinical, genomics, outcome data this population.
Abstract Background Despite the rise in number of approved novel oncology drugs, just over half all new cancer medicines by EMA between 2017 and 2021 were granted reimbursement Ireland HSE. Compassionate access programmes (CAPs) are a means providing managed to drugs which proven benefit but have not yet received full approval for state, or where requested indication has been authorised/licensed. Methods A retrospective review was performed patients attending The Mater hospital treatment...
To determine the safety and efficacy of adding anti-PD-L1 antibody durvalumab to induction FOLFOX preoperative chemotherapy in locally advanced esophageal adenocarcinoma.
NGS of cfDNA in HCC represents an alternative to tissue-based profiling, given the high tumor-plasma concordance.
<h3>Importance</h3> Brain metastasis (BrM) in gastroesophageal adenocarcinoma (GEA) is a rare and poorly understood phenomenon associated with poor prognosis. <h3>Objectives</h3> To examine the clinical genomic features of patients BrM from GEA evaluate factors survival. <h3>Design, Setting, Participants</h3> In this single-institution retrospective cohort study, 68 diagnosed between January 1, 2008, December 31, 2020, were identified via review billing codes imaging reports electronic...
The Covid-19 pandemic poses significant challenges for the management of patients with cancer. In our institution, we adapted delivery outpatient systemic anti-cancer therapy (SACT) by introducing a number 'risk-reducing' measures including pre-assessment screening.We sought to evaluate experience and perceptions cancer undergoing SACT during pandemic.Patients on were eligible participation. Data collected anonymous survey over 1 week period most intensive phase government restrictions....
In advanced pancreatic neuroendocrine neoplasms (PanNEN), there are little data detailing the frequency of genetic alterations identified in cell free DNA (cfDNA), plasma–tissue concordance detected alterations, and clinical utility cfDNA. Patients with metastatic PanNENs underwent cfDNA collection routine practice. Next-generation sequencing (NGS) matched tissue when available was performed. Clinical actionability variants annotated by OncoKB. Thirty-two samples were analyzed from 25...
Abstract Introduction Hepatic artery infusion (HAI) of chemotherapy has demonstrated disease control and suggested improvement in overall survival (OS) intrahepatic cholangiocarcinoma (IHC). We report herein the long-term results role molecular alterations a phase II clinical trial HAI plus systemic chemotherapy, with retrospective cohort patients treated at Memorial Sloan Kettering Cancer Center. Methods This secondary analysis single-institution, 2 unresectable IHC floxuridine (FUDR)...
Abstract Purpose: Intrahepatic cholangiocarcinoma (IHC) is a heterogeneous tumor. The hidden-genome classifier, supervised machine learning–based algorithm, was used to quantify tumor heterogeneity and improve classification. Experimental Design: A retrospective review of 1,370 patients with IHC, extrahepatic (EHC), gallbladder cancer (GBC), hepatocellular carcinoma (HCC), or biphenotypic tumors conducted. model classified 527 IHC based on genetic similarity EHC/GBC HCC. Genetic, histologic,...
Abstract Introduction Immune checkpoint inhibitor (ICI) combinations extend overall survival (OS) while anti-PD-1/L1 monotherapy is non-inferior to sorafenib in treatment-naïve, patients with advanced hepatocellular carcinoma (HCC). Clinicogenomic features are posited influence patient outcomes. Methods The primary objective of this retrospective study was define the clinical, pathologic, and genomic factors associated outcomes ICI therapy HCC. Patients histologically confirmed HCC treated...
Gastroesophageal junction (GEJ) adenocarcinoma is a rare cancer associated with poor prognosis. The genetic factors conferring predisposition to GEJ have yet be identified.We analyzed germline testing results from 23 381 patients undergoing tumor-normal sequencing, of which 312 individuals had adenocarcinoma. Genomic profiles and clinico-pathologic features were for the adenocarcinomas. Silencing ATM ATR was performed using validated short-interfering RNA species in GEJ, esophageal, gastric...
4029 Background: Induction FOLFOX followed by PET-directed CRT prior to surgery demonstrated positive results in the CALGB 80803 study. We investigated safety and efficacy of adding D, an anti-PD-L1 antibody, CRT. Methods: Patients (pts) with locally advanced esophageal/GEJ adenocarcinoma were enrolled. Pts received 2 cycles mFOLFOX6 repeat PET/CT. PET responders (≥35% reduction SUV (PETr)) 5-FU/capecitabine oxaliplatin RT 50.4Gy, while induction non-responders (PETnr) carboplatin/paclitaxel...
513 Background: Isocitrate dehydrogenase 1 and 2 (IDH1/2) play a key role in cellular metabolism epigenetic regulation. Conserved missense IDH1 mutations lead to an accumulation of the onco-metabolite 2-hydroxygluterate, which drives oncogenesis inhibits differentiation. Ivosidenib is now approved for mutant BTC following results phase III ClarIDHy trial. It remains unclear what are long-term outcomes patients (pts) with treated chemotherapy, targeted therapy, immunotherapy. Methods: This...